BridgeBio Pharma stockholders elect four Class I directors and approve say-on-pay

BridgeBio Pharma, Inc.

Four director nominees elected: Momtazee (126.98M for), McCormick (126.13M for), Scott (131.25M for), Valantine (107.39M for); 14.89M broker non-votes.
Non-binding advisory vote on executive compensation passed with 104.00M for, 29.90M against, 45.6k abstentions.
Ratification of Deloitte & Touche as auditor for FY2023 approved with 148.80M for, 22.0k against.
Total shares represented at meeting: 148.84M out of 160.50M outstanding.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

BridgeBio Pharma, Inc. shareholders approved Election of four Class I director nominees to hold office until the 2026 Annual Meeting at the 2023-06-21 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-21

Exact text from the filing

Proposal 1 - Election of Directors. The Company’s stockholders elected the four (4) director nominees below to the Company’s Board of Directors as Class I directors to hold office until the 2026 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified. Director Nominee Votes For Votes Withheld James C. Momtazee 126,983,947 6,964,797 Frank McCormick, Ph.D. 126,128,725 7,820,019 Randal W. Scott, Ph.D. 131,253,639 2,695,105 Hannah A. Valantine, M.D. 107,393,329 26,555,415 There were 14,889,405 broker non-votes regarding this proposal.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

BridgeBio Pharma, Inc. shareholders approved Non-binding advisory vote on compensation of named executive officers at the 2023-06-21 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-06-21

Exact text from the filing

Proposal 2 - Non-binding Advisory Vote on Compensation of Named Executive Officers. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers. Votes For Votes Against Abstentions 104,001,511 29,901,611 45,622 There were 14,889,405 broker non-votes regarding this proposal.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

BridgeBio Pharma, Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-21 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-21

Exact text from the filing

Proposal 3 - Ratification of Appointment of Independent Registered Accounting Firm. The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023. Votes For Votes Against Abstentions 148,795,806 21,960 20,383 There were zero broker non-votes regarding this proposal.

View on SEC.gov

160 shareholder votes filed in the last 30 days. Browse all shareholder votes →

BridgeBio Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-030932

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.